Mounjaro Weight Loss Results

Mounjaro Before and After Results: Your Weight Loss Timeline

Quick Answer: Mounjaro can produce substantial weight loss, but results vary between patients and build gradually over time. In the 72-week SURMOUNT-1 trial, average weight change was approximately 15.0% with 5 mg, 19.5% with 10 mg and 20.9% with 15 mg tirzepatide, compared with 3.1% with placebo. Your own results can differ according to treatment response, tolerability, maintenance dose, lifestyle and other individual factors. The first month is only the beginning of treatment, so early scale changes should not be used to predict your eventual result.

20.9% average weight reduction at 15 mg in SURMOUNT-1 at 72 weeks

2,539 participants in the SURMOUNT-1 trial

72 weeks duration of the landmark SURMOUNT-1 trial

Clinical Evidence What Do Mounjaro Clinical Trials Show? Much of the evidence for tirzepatide in people living with overweight or obesity comes from the SURMOUNT clinical trial programme. SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight with at least one weight-related complication, who did not have type 2 diabetes. Participants received tirzepatide or placebo alongside lifestyle intervention for 72 weeks. If you are considering treatment rather than simply researching the trial results, you can find information on available strengths, suitability and Happy Pharmacy's prescribing service on our Mounjaro weight loss injection page. SURMOUNT-1 Results at 72 Weeks

Outcome	5 mg	10 mg	15 mg	Placebo
Average weight change	−15.0%	−19.5%	−20.9%	−3.1%
Lost at least 5%	85%	89%	91%	35%
Lost at least 20%	30%	50%	57%	3%

These are trial averages, not personal forecasts. Someone taking Mounjaro may lose more or less than these figures. Trial participants also received lifestyle intervention alongside medication.

SURMOUNT-5: Mounjaro Compared With Wegovy SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity who did not have diabetes. At 72 weeks, average weight change was approximately 20.2% with tirzepatide and 13.7% with semaglutide. This supports a greater average weight reduction with tirzepatide in that trial population, although the most suitable treatment for an individual depends on more than average weight-loss results.

Your First Month Your First Month on Mounjaro: Week by Week The first four weeks of Mounjaro treatment are spent on the 2.5 mg starting dose. This is the beginning of the dose-escalation schedule, so the first month is better viewed as a period for getting used to treatment and monitoring your response than as a test of how much weight you can lose. Some people notice changes in appetite or eating patterns during the first month, while others notice relatively little at first. Weight change also varies considerably between individuals, so there is no reliable number of kilograms that everyone should expect to lose in a particular week.

Week	What Is Happening?	What to Focus On
Week 1	You take your first 2.5 mg dose. Appetite or fullness may begin to feel different, although some people notice little change initially.	Get comfortable with your weekly injection routine and pay attention to how you tolerate treatment.
Week 2	You remain on 2.5 mg. You may become more familiar with any changes in appetite, meal size or gastrointestinal symptoms.	Continue treatment as prescribed rather than judging progress from short-term scale fluctuations.
Week 3	You are still on the starting dose. Weight, appetite and side-effect patterns can differ substantially between patients.	Focus on consistency and note anything you may need to discuss with your prescribing team.
Week 4	You complete four weeks at 2.5 mg. Under the licensed schedule, the next dose is normally 5 mg once weekly.	Review how treatment has been tolerated and follow the dosing plan agreed with your prescriber.

Do not compare your first month too closely with somebody else's. Clinical trials report average changes across groups over much longer periods. They do not provide a dependable week-by-week prediction for an individual patient.

What If You Have Not Lost Much Weight in the First Month? Limited movement on the scales during the first four weeks does not by itself mean Mounjaro is ineffective. You are still at the beginning of treatment, and your longer-term response is more informative than the result from an individual week. Your dose should not be increased early simply because you want faster weight loss. You can see how treatment progresses from 2.5 mg through the available dose strengths in our Mounjaro dose schedule guide. If symptoms such as nausea, diarrhoea, constipation or vomiting are affecting treatment, you can find out more about Mounjaro side effects with our useful guide, and speak to your prescribing team if symptoms are severe or persistent.

Around Three Months Mounjaro Results After 3 Months By around three months, treatment has moved beyond the initial starting phase and patients may have progressed through several dose steps depending on their prescribed schedule and tolerability. Weight loss can become more noticeable during this period, but there is no single percentage that everybody should have lost by three months. SURMOUNT-1 was designed primarily to assess longer-term outcomes at 72 weeks rather than provide a personalised month-three target. Your progress should therefore be judged as a trend rather than against a fixed online benchmark. Changes in weight, waist measurement, eating behaviour, treatment tolerance and relevant health markers can all help your clinical team assess response.

If you are unsure whether your progress is appropriate, do not increase your dose independently. Your prescriber can review your current dose, response and tolerability.

Around Six Months Mounjaro Results After 6 Months By six months, patients who have remained on treatment have had substantially more time for weight loss to accumulate than during the starting phase. Some will have reached a higher maintenance dose, while others may remain on 5 mg or 10 mg if that is appropriate for their response and tolerability. The licensed adult maintenance doses are 5 mg, 10 mg and 15 mg once weekly. Higher doses produced greater average weight reduction in SURMOUNT-1, but this does not mean every patient should progress to 15 mg. Six Months Is Also an Important Clinical Review Point Current UK product information states that if a patient has lost less than 5% of their initial body weight six months after titrating to their highest tolerated dose, a decision should be made about whether continuing treatment remains appropriate.

This review point is different from saying that everyone should lose 5% within their first six months from the very first injection. It applies after titration to the highest tolerated dose.

Longer-Term Results Mounjaro Results After 12 Months and Beyond Mounjaro weight loss generally develops over many months rather than following a short, fixed course. By 12 months, patients who remain on treatment may have accumulated substantial weight loss, although the amount differs considerably between individuals. SURMOUNT-1 continued for 72 weeks, or roughly 16½ months. At that point, average weight change was 15.0% with 5 mg, 19.5% with 10 mg and 20.9% with 15 mg. What Do Those Percentages Mean in Kilograms? Percentage loss can be easier to understand by converting it into kilograms. The table below is simply a mathematical illustration. It does not predict the result a particular patient will achieve.

Starting Weight	5% Loss	10% Loss	15% Loss	20% Loss
80 kg	4 kg	8 kg	12 kg	16 kg
100 kg	5 kg	10 kg	15 kg	20 kg
120 kg	6 kg	12 kg	18 kg	24 kg
140 kg	7 kg	14 kg	21 kg	28 kg

Results Timeline Mounjaro Weight Loss Timeline at a Glance There is no medically reliable schedule that says exactly how many kilograms you should lose in each month. A more useful way to understand the timeline is to look at how treatment develops.

Month 1 Starting Phase 2.5 mg starting dose and early treatment response

Month 3 Progress Building Weight-loss trend may become clearer as treatment progresses

Month 6 Clinical Review Longer-term response and highest tolerated dose can be assessed

72 Weeks Trial Benchmark SURMOUNT-1 provides the strongest dose-specific outcome data here

Individual Results Why Mounjaro Results Vary Between People Clinical trials provide useful averages, but they cannot tell you exactly how your weight will change. Several factors can influence individual treatment outcomes.

Treatment Factors

The maintenance dose that is clinically appropriate for you
How consistently treatment is taken
Whether side effects limit dose progression or food intake
How long you remain on treatment

Lifestyle and Individual Factors

Your starting body weight and body composition
Overall energy intake and dietary pattern
Protein intake and physical activity
Medical conditions and medicines that affect weight

Does a Higher Mounjaro Dose Always Mean Better Results? SURMOUNT-1 showed a dose-response relationship at group level, with greater average weight reduction at 10 mg and 15 mg than at 5 mg. However, treatment is not a competition to reach the maximum dose. The recommended adult maintenance doses are 5 mg, 10 mg and 15 mg, and your prescriber should decide whether an increase is needed based on response and tolerability. Diet and Nutrition Mounjaro is licensed for weight management alongside a reduced-calorie diet and increased physical activity. Because appetite may be substantially reduced, food quality remains important even when total food intake falls. We explain what to eat on Mounjaro in more detail, including how to prioritise protein, fibre, hydration and nutrient-rich foods during treatment. Muscle Preservation Weight loss can include both fat mass and lean mass. Adequate protein intake and resistance-based activity can help support muscle preservation during weight reduction.

Slower Progress What If Mounjaro Is Not Producing the Results You Expected? A slower response than somebody else's does not necessarily mean treatment has failed. Short-term weight can fluctuate, and people progress through treatment differently. If progress appears limited over a longer period, your clinician may review your current dose, how consistently treatment is being used, nutrition and activity, side effects, other medicines and whether continued treatment remains appropriate.

Do not increase your Mounjaro dose yourself to try to accelerate weight loss. Dose increases should follow the licensed schedule and your prescriber's instructions.

Maintaining Results What Happens to Weight After Stopping Mounjaro? SURMOUNT-4 examined what happened when people who had initially received tirzepatide were either continued on treatment or switched to placebo. Those switched to placebo regained weight on average, while participants who continued tirzepatide maintained and extended their weight reduction. This supports the view of obesity treatment as a longer-term clinical management issue rather than assuming that a short course of medication will permanently change weight regulation.

Decisions about continuing, reducing or stopping Mounjaro should be made with your prescribing clinician. Do not stop solely because you have reached a particular number on the scales without discussing what happens next.

Eligibility Could You Be Eligible for Mounjaro? Mounjaro is a prescription-only medicine and suitability must be assessed by a qualified prescriber. Eligibility depends on factors including BMI, medical history, current medicines and relevant weight-related health conditions. If you are unsure whether your BMI meets the relevant threshold, use our BMI eligibility calculator to check your BMI and understand the weight-loss injection eligibility pathways used by Happy Pharmacy.

Key Questions Mounjaro Results: Key Points How much weight can you lose on Mounjaro? In SURMOUNT-1, average weight change after 72 weeks was approximately 15.0% with 5 mg, 19.5% with 10 mg and 20.9% with 15 mg tirzepatide. These are group averages and should not be treated as a guarantee of individual weight loss. How quickly does Mounjaro work for weight loss? Some people notice changes in appetite early in treatment, but meaningful weight-loss results develop over time. The first four weeks are spent at the 2.5 mg starting dose and should not be used to predict the eventual long-term result. How do you know if Mounjaro is working? Look at the longer-term trend rather than a single week's weight. Current UK guidance includes a formal review if less than 5% of initial body weight has been lost six months after titrating to the highest tolerated dose.

FAQs Frequently Asked Questions: Mounjaro Results

SURMOUNT-1 reported average weight changes of approximately 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg after 72 weeks. Individual results vary and may be higher or lower.

There is no reliable kilogram figure that applies to everyone in month one. The first four weeks are spent at the 2.5 mg starting dose, and response varies considerably. Early weight change should not be used to predict your eventual result.

You begin with the 2.5 mg once-weekly starting dose. Some people notice changes in appetite or fullness while others notice little initially. Your priority should be following the prescribed schedule and monitoring how you tolerate treatment.

You remain on 2.5 mg for the first four weeks. During this period you can monitor appetite, weight trend and tolerability. After completing four weeks, the licensed schedule normally progresses to 5 mg once weekly.

Limited weight loss during the starting phase does not automatically mean treatment is ineffective. Mounjaro is escalated gradually and longer-term response is more meaningful than the result from the first four weeks.

There is no single three-month percentage that should be expected by every patient. Trial evidence is strongest for longer-term outcomes, and early response differs according to the individual and the dose progression that is clinically appropriate.

In the 72-week SURMOUNT-5 head-to-head trial, average weight change was approximately 20.2% with tirzepatide and 13.7% with semaglutide. This demonstrates a greater average reduction with tirzepatide in that trial population, but treatment choice should also consider suitability, side effects, medical history and prescriber advice.

Yes. 5 mg is a recommended adult maintenance dose. In SURMOUNT-1, participants assigned to 5 mg lost an average of approximately 15.0% of their starting weight at 72 weeks.

No. The recommended adult maintenance doses are 5 mg, 10 mg and 15 mg. Higher doses produced greater average weight reduction in SURMOUNT-1, but the appropriate dose for you depends on your response and tolerability.

Assess progress over time rather than from one week's weight. Current UK product information says that if less than 5% of initial body weight has been lost six months after titrating to the highest tolerated dose, the benefits of continuing treatment should be reviewed.

Weight loss does not normally continue at the same rate indefinitely. The rate can vary throughout treatment and may slow over time. A slower period does not automatically mean the medicine has stopped working.

In SURMOUNT-4, participants switched from tirzepatide to placebo regained weight on average, while those who continued treatment maintained and extended their weight reduction. Any decision to stop should be discussed with your prescriber.

Mounjaro is licensed for weight management alongside a reduced-calorie diet and increased physical activity. The major clinical trials also included lifestyle intervention, so medication should not be viewed in isolation from nutrition and activity.

Eligibility depends on factors including BMI, medical history, current medicines and weight-related health conditions. Final suitability must be assessed by a qualified prescriber.

Considering Mounjaro for Weight Loss? Complete a clinical assessment with Happy Pharmacy's UK prescribing team to find out whether Mounjaro is suitable for you. Check Your Eligibility →

References